Eradication of LIG4-deficient glioblastoma cells by the combination of PARP inhibitor and alkylating agent.

In conclusion, PARP inhibitor combined with DNA damage inducing agents can be utilized in patients with glioblastoma displaying defects in D-NHEJ. PMID: 30627327 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research